



Ambu A/S - Capital increase in connection with exercise of warrants issued

In April 2012, Ambu A/S issued 507,600 warrants and in December 2013 400,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 2.50. 69 employees participate in the 2012 scheme and 52 employees participate in the 2013 scheme. In both cases, the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 1 February 2017 in connection with Ambu's interim financial report for Q1 2016/17.

Since 1 February 2017, instructions have been received to exercise warrants as follows:

- 2012 scheme: Three employees have issued instructions to exercise a total of 34,800 warrants at the agreed exercise price of DKK 39.50
- 2013 scheme: 31 employees have issued instructions to exercise a total of 268,000 warrants at the agreed exercise price of DKK 66.30.

Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 757,000 from DKK 120,967,800 to DKK 121,724,800 through the issue of 302,800 Class B shares. The share capital is now divided into 41,825,920 B shares of DKK 2.50 each and 6,864,000 A-shares of DKK 2.50 each.

Following this and in consideration of the employees having left the company, there are no warrants remaining under the 2012 scheme, while 80,000 remaining warrants under the 2013 scheme are now being held by 12 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 15 February 2017 under the ISIN code of Ambu A/S' existing B shares (DK0060591204).

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

About Ambu

Since 1937, breakthrough ideas have driven Ambu's work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu bag and the legendary Blue Sensor® electrodes to our latest landmark solutions such as the aScope™ – the world's first single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu has more than 2,350 employees in Europe, North America, Asia and the Pacific region. You can find more information about Ambu on our website: www.ambu.com.